2024

Gögenur, M. et al. (2024) Time from colorectal cancer surgery to adjuvant chemotherapy – post hoc analysis of the SCOT trial. JAMA Surgery, 159(8), pp. 865-871. (doi: 10.1001/jamasurg.2024.1555) (PMID:38865139)

Domingo, E. et al. (2024) Prognostic and predictive value of Immunoscore in stage III colorectal cancer: pooled analysis of 2,608 cases from the SCOT and IDEA-HORG studies. Journal of Clinical Oncology, (doi: 10.1200/JCO.23.01648) (PMID:38484206) (Early Online Publication)

Pennel, K. A.F. et al. (2024) JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors. Journal of Experimental and Clinical Cancer Research, 43, 64. (doi: 10.1186/s13046-024-02958-4)

2023

Lemanska, A., Harkin, A., Iveson, T., Kelly, C. , Saunders, M. and Faithfull, S. (2023) The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial. ESMO Open, 8(6), 102063. (doi: 10.1016/j.esmoop.2023.102063) (PMID:37988949) (PMCID:PMC10774973)

Frei, A. L. et al. (2023) Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets. Journal of Pathology: Clinical Research, 9(6), pp. 449-463. (doi: 10.1002/cjp2.342) (PMID:37697694) (PMCID:PMC10556275)

Saunders, M. P. et al. (2023) SCOT: tumour sidedness and the influence of adjuvant chemotherapy duration on disease free survival (DFS). Clinical Colorectal Cancer, 22(2), pp. 231-237. (doi: 10.1016/j.clcc.2023.02.005) (PMID:36967267)

2021

Fontana, E. et al. (2021) Early-onset colorectal adenocarcinoma in the IDEA database: treatment adherence, toxicities, and outcomes with 3 and 6 months of adjuvant fluoropyrimidine and oxaliplatin. Journal of Clinical Oncology, 39(36), pp. 4009-4019. (doi: 10.1200/jco.21.02008) (PMID:34752136)

Hanna, C. R. et al. (2021) Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clinical Colorectal Cancer, 20(3), pp. 236-244. (doi: 10.1016/j.clcc.2021.04.001) (PMID:33992542)

Alexander, P.G. et al. (2021) The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. British Journal of Cancer, 124, pp. 786-796. (doi: 10.1038/s41416-020-01168-x) (PMID:33223535)

Blinman, P. et al. (2021) Patients’ preferences for 3 months vs 6 months of adjuvant chemotherapy for colon cancer. JNCI Cancer Spectrum, 5(1), pkaa107. (doi: 10.1093/jncics/pkaa107) (PMID:34159294) (PMCID:PMC7883552)

Iveson, T. J. et al. (2021) Duration of adjuvant doublet chemotherapy (3 or 6 months) in patients with high-risk stage II colorectal cancer. Journal of Clinical Oncology, 39(6), pp. 631-641. (doi: 10.1200/JCO.20.01330) (PMID:33439695)

2020

André, T. et al. (2020) Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncology, 21(12), pp. 1620-1629. (doi: 10.1016/S1470-2045(20)30527-1) (PMID:33271092) (PMCID:PMC7786835)

Roseweir, A. K. et al. (2020) Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. Journal of Pathology: Clinical Research, 6(4), pp. 283-296. (doi: 10.1002/cjp2.171) (PMID:32401426) (PMCID:PMC7578335)

2019

Iveson, T. et al. (2019) 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health Technology Assessment, 23(64), (doi: 10.3310/hta23640) (PMID:31852579)

Law, P. J. et al. (2019) Association analyses identify 31 new risk loci for colorectal cancer susceptibility. Nature Communications, 10, 2154. (doi: 10.1038/s41467-019-09775-w) (PMID:31089142) (PMCID:PMC6517433)

Gray, V. et al. (2019) Pattern recognition receptor polymorphisms as predictors of oxaliplatin benefit in colorectal cancer. Journal of the National Cancer Institute, 111(8), pp. 828-836. (doi: 10.1093/jnci/djy215) (PMID:30649440) (PMCID:PMC6695319)

2018

Iveson, T. J. et al. (2018) 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncology, 19(4), pp. 562-578. (doi: 10.1016/S1470-2045(18)30093-7) (PMID:29611518) (PMCID:PMC5883334)

2011

Paul, J. , Iveson, T., Midgely, R., Harkin, A., Masterton, M., Alexander, L. and Cassidy, J. (2011) Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study. Trials, 12(Sup.1), A30. (doi: 10.1186/1745-6215-12-S1-A30)

Boyd, K.A. , Briggs, A. , Paul, J. , Iveson, T., Midgely, R., Harkin, A., Bates, G., Alexander, L. and Cassidy, J. (2011) Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting? Trials, 12, A41. (doi: 10.1186/1745-6215-12-S1-A41)

Articles

Gögenur, M. et al. (2024) Time from colorectal cancer surgery to adjuvant chemotherapy – post hoc analysis of the SCOT trial. JAMA Surgery, 159(8), pp. 865-871. (doi: 10.1001/jamasurg.2024.1555) (PMID:38865139)

Domingo, E. et al. (2024) Prognostic and predictive value of Immunoscore in stage III colorectal cancer: pooled analysis of 2,608 cases from the SCOT and IDEA-HORG studies. Journal of Clinical Oncology, (doi: 10.1200/JCO.23.01648) (PMID:38484206) (Early Online Publication)

Pennel, K. A.F. et al. (2024) JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors. Journal of Experimental and Clinical Cancer Research, 43, 64. (doi: 10.1186/s13046-024-02958-4)

Lemanska, A., Harkin, A., Iveson, T., Kelly, C. , Saunders, M. and Faithfull, S. (2023) The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial. ESMO Open, 8(6), 102063. (doi: 10.1016/j.esmoop.2023.102063) (PMID:37988949) (PMCID:PMC10774973)

Frei, A. L. et al. (2023) Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets. Journal of Pathology: Clinical Research, 9(6), pp. 449-463. (doi: 10.1002/cjp2.342) (PMID:37697694) (PMCID:PMC10556275)

Saunders, M. P. et al. (2023) SCOT: tumour sidedness and the influence of adjuvant chemotherapy duration on disease free survival (DFS). Clinical Colorectal Cancer, 22(2), pp. 231-237. (doi: 10.1016/j.clcc.2023.02.005) (PMID:36967267)

Fontana, E. et al. (2021) Early-onset colorectal adenocarcinoma in the IDEA database: treatment adherence, toxicities, and outcomes with 3 and 6 months of adjuvant fluoropyrimidine and oxaliplatin. Journal of Clinical Oncology, 39(36), pp. 4009-4019. (doi: 10.1200/jco.21.02008) (PMID:34752136)

Hanna, C. R. et al. (2021) Three versus six months of adjuvant doublet chemotherapy for patients with colorectal cancer: a multi-country cost-effectiveness and budget impact analysis. Clinical Colorectal Cancer, 20(3), pp. 236-244. (doi: 10.1016/j.clcc.2021.04.001) (PMID:33992542)

Alexander, P.G. et al. (2021) The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. British Journal of Cancer, 124, pp. 786-796. (doi: 10.1038/s41416-020-01168-x) (PMID:33223535)

Blinman, P. et al. (2021) Patients’ preferences for 3 months vs 6 months of adjuvant chemotherapy for colon cancer. JNCI Cancer Spectrum, 5(1), pkaa107. (doi: 10.1093/jncics/pkaa107) (PMID:34159294) (PMCID:PMC7883552)

Iveson, T. J. et al. (2021) Duration of adjuvant doublet chemotherapy (3 or 6 months) in patients with high-risk stage II colorectal cancer. Journal of Clinical Oncology, 39(6), pp. 631-641. (doi: 10.1200/JCO.20.01330) (PMID:33439695)

André, T. et al. (2020) Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncology, 21(12), pp. 1620-1629. (doi: 10.1016/S1470-2045(20)30527-1) (PMID:33271092) (PMCID:PMC7786835)

Roseweir, A. K. et al. (2020) Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. Journal of Pathology: Clinical Research, 6(4), pp. 283-296. (doi: 10.1002/cjp2.171) (PMID:32401426) (PMCID:PMC7578335)

Iveson, T. et al. (2019) 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT. Health Technology Assessment, 23(64), (doi: 10.3310/hta23640) (PMID:31852579)

Law, P. J. et al. (2019) Association analyses identify 31 new risk loci for colorectal cancer susceptibility. Nature Communications, 10, 2154. (doi: 10.1038/s41467-019-09775-w) (PMID:31089142) (PMCID:PMC6517433)

Gray, V. et al. (2019) Pattern recognition receptor polymorphisms as predictors of oxaliplatin benefit in colorectal cancer. Journal of the National Cancer Institute, 111(8), pp. 828-836. (doi: 10.1093/jnci/djy215) (PMID:30649440) (PMCID:PMC6695319)

Iveson, T. J. et al. (2018) 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncology, 19(4), pp. 562-578. (doi: 10.1016/S1470-2045(18)30093-7) (PMID:29611518) (PMCID:PMC5883334)

Paul, J. , Iveson, T., Midgely, R., Harkin, A., Masterton, M., Alexander, L. and Cassidy, J. (2011) Choice of randomisation time-point in non-inferiority studies of reduced treatment duration: experience from the SCOT study. Trials, 12(Sup.1), A30. (doi: 10.1186/1745-6215-12-S1-A30)

Boyd, K.A. , Briggs, A. , Paul, J. , Iveson, T., Midgely, R., Harkin, A., Bates, G., Alexander, L. and Cassidy, J. (2011) Analysis of adverse events and quality of life data for an economic evaluation of adjuvant chemotherapy in colorectal cancer: when can we stop collecting? Trials, 12, A41. (doi: 10.1186/1745-6215-12-S1-A41)